Ensysce Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
ENSC$0.33-8.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements (Unaudited)Consolidated Balance Sheets
Consolidated Balance Sheets
| March 31, 2026 · December 31, 2025 | ||||
|---|---|---|---|---|
| (Unaudited) | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $745,482 | $4,310,354 | ||
| Unbilled receivable | - | 420,345 | ||
| Prepaid expenses and other current assets | 1,263,058 | 2,514,319 | ||
| Total current assets | 2,008,540 | 7,245,018 | ||
| Property and equipment, net | 117,596 | 124,129 | ||
| Other assets | 41,667 | 83,332 | ||
| Total assets | $2,167,803 | $7,452,479 | ||
| Liabilities and stockholders’ equity (deficit) | ||||
| Current liabilities: | ||||
| Accounts payable | $1,610,186 | $3,267,610 | ||
| Accrued expenses and other liabilities | 980,780 | 993,411 | ||
| Notes payable and accrued interest | 245,849 | 306,708 | ||
| Total current liabilities | 2,836,815 | 4,567,729 | ||
| Total liabilities | $2,836,815 | $4,567,729 | ||
| Commitments and contingencies (Note 6) | - | - | ||
| Stockholders’ equity (deficit) | ||||
| Preferred stock, $0.0001 par value, 1,500,000 shares authorized at March 31, 2026 and December 31, 2025; 4,000 shares issued at March 31, 2026 and December 31, 2025; 1,405 and 3,305 shares outstanding at March 31, 2026 and December 31, 2025, respectively; $1,545,500 and $3,635,500 liquidation preference at March 31, 2026 and December 31, 2025, respectively | $ | - | $ | - |
| Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2026 and December 31, 2025; 9,277,825 and 4,574,983 shares issued at March 31, 2026 and December 31, 2025, respectively; 9,277,819 and 4,574,977 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 929 | 459 | ||
| Additional paid-in capital | 142,935,443 | 142,933,260 | ||
| Accumulated deficit | (143,276,414) | (139,719,999) | ||
| Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) | (340,042) | 3,213,720 | ||
| Noncontrolling interests in stockholders’ equity (deficit) | (328,970) | (328,970) | ||
| Total stockholders’ equity (deficit) | (669,012) | 2,884,750 | ||
| Total liabilities and stockholders’ equity (deficit) | $2,167,803 | $7,452,479 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.